Evolent Announces Third Quarter 2024 Results

Revenue of $621.4 million, an increase of$110.4 million or 21.6%, from the three months ended September 30, 2023. Net loss attributable to common shareholders of Evolent Health, Inc. of $(31.2) million and a net loss margin of (5.0)$31.8 million resulting in an Adjusted EBITDA margin of 5.1%. Revises outlook for Adjusted EBITDA for 2024. Reiterates average annual long-term revenue and average Adjusted EBITDA growth rate targets. Announces record six new contract agreements in the qua ...